An observational study in Muscle Spasticity, sponsored by Allergan. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-14.
Sponsored by Allergan · Observational
This is a retrospective study of patients with spasticity in the Spanish population.
704 studies on the registry are indexed under Muscle Spasticity; 149 are open to participants now.
This study's enrollment of 235 is above the median of 60 across 162 observational studies indexed under Muscle Spasticity.
Browse Muscle Spasticity studies →Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with diagnosis of spasticity are selected from rehabilitation departments within the Spanish health system.
Exclusion Criteria:
This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
Other: No treatment
There was no treatment in this study.
Physician Assessment of Spasticity
The physician assessed spasticity as per local standard practice. Not enough data was collected for analysis of this outcome measure.
Time frame: Baseline
Physician Assessment of Spasticity
The physician assessed spasticity as per local standard practice. Not enough data was collected for analysis of this outcome measure.
Time frame: Month 12
| Milestone | All Participants |
|---|---|
| Started | 235 |
| Completed | 189 |
| Not completed | 46 |
The physician assessed spasticity as per local standard practice. Not enough data was collected for analysis of this outcome measure.
No measurements were reported for this outcome.
The physician assessed spasticity as per local standard practice. Not enough data was collected for analysis of this outcome measure.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | — | — | — |
| Age, Customized(Participants) | All Participants |
|---|---|
| 18 to 25 years | 21 |
| 26 to 35 years | 21 |
| 36 to 45 years | 43 |
| 46 to 55 years | 48 |
| 56 to 65 years | 57 |
| >65 years | 45 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 94 |
| Male | 141 |
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergan